Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 8 of 8 results for amivantamab

  1. Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)

    Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA850

  2. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

    In development Reference number: GID-TA11279 Expected publication date:  21 January 2026

    Technology appraisal guidance
    In development

  3. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 December 2025.

    Technology appraisal guidance
    In consultation

  5. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    In development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  8. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

    Technology appraisal guidance
    Published
    12 May 2025

    Sections for TA1062